Pre-Conference Workshop Day

Tuesday | 16 April 2024

9:00 - 10:00 Check In, Morning Coffee & Light Breakfast

10:00 - 12:00 Workshop A

Unveiling the Potential of JAK Inhibitors in Dermatology

Join us for an immersive workshop that delves into the promising realm of JAK inhibitor drug development for dermatology indications. Explore their potential as first-line or adjunctive therapies, assess their safety profiles, and tackle the unique challenges surrounding small molecule JAK inhibitors in dermatological treatments, all while networking with industry experts.

Join this session to discuss:

  • What recent advancements and clinical trial outcomes demonstrate the potential of JAK inhibitors as groundbreaking therapies in the dermatology landscape, and how can pharmaceutical companies capitalise on these findings?
  • What are the key safety considerations and risk mitigation strategies when developing JAK inhibitors for dermatology, and how can these be aligned with
    regulatory requirements to ensure patient wellbeing
  • What innovative approaches and technologies can accelerate the development of small molecule JAK inhibitors and address the specific formulation and delivery challenges they present, paving the way for more effective and patient-friendly

Workshop Leader


Farzan Solimani
Charité, Universitätsmedizin

12:00 - 13:00 Lunch Break & Networking

13:00 - 16:00 Workshop B

Unlocking Dermatology Drug Development Success: Innovations in Patient Recruitment Strategies

Join us for an engaging workshop that explores cutting-edge solutions to the patient recruitment challenges pharmaceutical companies face in dermatology drug
development. Discover actionable insights and strategies to accelerate your clinical studies and bring transformative treatments to market faster.

Participate to learn:

  • How can pharmaceutical companies leverage advanced digital technologies and data analytics to identify and engage suitable dermatology clinical trial candidates
  • What novel patient-centric approaches can be employed to enhance participant retention and compliance throughout the course of dermatology clinical studies?
  • In a rapidly evolving regulatory landscape, what best practices and compliance considerations are critical for pharmaceutical companies aiming to navigate dermatology drug development successfully while maintaining patient safety and data integrity?

Workshop Leader


Betsy Hughes-Formella
Co-Founder & Chief Scientific Officer
Dermaliq Therapeutics


Neal Koller
Chief Executive Officer
Alphyn Biologics

16:00 End of Pre-Conference Workshop Day